AcuCort's CEO Jonas Jönmark will take part in a live interview on Tuesday 6 October at 12.00 CET. The interview will focus on AcuCort's rights issue, the FDA process in the US and the company's continued international expansion.
During the interview (in Swedish), Jonas Jönmark will discuss how the proceeds from the rights issue will be used, preparations for the planned New Drug Application (NDA) for Zeqmelit® in the US, and plans for a future launch in the US market. He will also comment on AcuCort's key upcoming milestones.
Viewers will have the opportunity to submit questions via the live chat during the broadcast.
Time: Tuesday 6 October at 12.00 CET
Watch the live broadcast: https://www.youtube.com/watch?v=rZSooPVl0mw
For further information:
Jonas Jönmark, CEO, AcuCort AB
Phone: 070 365 5400
E-mail: jonas.jonmark@acucort.com
About AcuCort AB (publ)
AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland, where the product is also marketed. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit www.acucort.se for more information.